Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for AstraZeneca Pharma India's Equity-to-Asset or its related term are showing as below:
NSE:ASTRAZEN'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.43 Med: 0.54 Max: 0.66
Current: 0.44
During the past 13 years, the highest Equity to Asset Ratio of AstraZeneca Pharma India was 0.66. The lowest was 0.43. And the median was 0.54.
NSE:ASTRAZEN's Equity-to-Asset is ranked worse than 70.78% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs NSE:ASTRAZEN: 0.44
AstraZeneca Pharma India (NSE:ASTRAZEN) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
AstraZeneca Pharma India Equity-to-Asset Related Terms
AstraZeneca Pharma India Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Pharma India Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where AstraZeneca Pharma India's Equity-to-Asset falls into.
AstraZeneca Pharma India Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
AstraZeneca Pharma India's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca Pharma India (NSE:ASTRAZEN) has a Equity-to-Asset of 0.00 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AstraZeneca Pharma India and its competitors. Over the past decade, AstraZeneca Pharma India's Equity-to-Asset has ranged from 0.43 to 0.66. According to the industry distribution chart, AstraZeneca Pharma India ranks #712 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 70.8%.
Is AstraZeneca Pharma India's Equity-to-Asset too high?
AstraZeneca Pharma India's current Equity-to-Asset is 0.00. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 0.66. Based on the distribution chart, AstraZeneca Pharma India ranks #712 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, AstraZeneca Pharma India has a GF Score™ of 91/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca Pharma India's Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, AstraZeneca Pharma India ranks #712 out of 1006 companies for Equity-to-Asset. This places AstraZeneca Pharma India in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Historically, AstraZeneca Pharma India's own Equity-to-Asset has ranged from 0.43 to 0.66 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on AstraZeneca Pharma India and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca Pharma India's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca Pharma India stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca Pharma India (NSE:ASTRAZEN) is currently considered Possible Value Trap. The stock's GF Value™ is ₹11,371.97, compared to a current price of ₹7,753.00 — trading 31.8% below its estimated fair value. The current Equity-to-Asset is 0.00. AstraZeneca Pharma India's overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For AstraZeneca Pharma India (NSE:ASTRAZEN), the current Equity-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca Pharma India (NSE:ASTRAZEN) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca Pharma India stock appears to be undervalued.
The current stock price of ₹7,753.00 is trading 31.8% below its estimated GF Value™ of ₹11,371.97.
GuruFocus considers AstraZeneca Pharma India to be Possible Value Trap.
Key valuation signals for NSE:ASTRAZEN:
Equity-to-Asset: 0.00
GF Value™: ₹11,371.97 vs. price of ₹7,753.00 (31.8% below fair value)
No single metric tells the full story. See the NSE:ASTRAZEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
91GF Score
Get the complete analysis for NSE:ASTRAZEN
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTRAZEN has been successfully added to your 
